Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

971TiP - Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Date

10 Sep 2022

Session

Poster session 04

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Mustafa Ozguroglu

Citation

Annals of Oncology (2022) 33 (suppl_7): S438-S447. 10.1016/annonc/annonc1063

Authors

M. Ozguroglu1, B. Levy2, H. Horinouchi3, J. Yu4, E. Grainger5, P. Phuong6, D.A. Peterson7, M. Newton8, A. Spira9

Author affiliations

  • 1 Department Of Internal Medicine, Division Of Medical Oncology, Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, 35440 - Istanbul/TR
  • 2 N/a, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, 21231 - Washington, D.C./US
  • 3 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, 271509 - Jinan/CN
  • 5 N/a, AstraZeneca, CB2 1RY - Cambridge/GB
  • 6 Clinical Sciences, Arcus Biosciences, 94545 - Hayward/US
  • 7 N/a, AstraZeneca, 02451 - Waltham/US
  • 8 N/a, AstraZeneca, 20878 - Gaithersburg/US
  • 9 Clinical Research, Virginia Cancer Specialists Research Institute and US Oncology Research, 22031 - Fairfax/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 971TiP

Background

The PACIFIC trial established up to 12 months consolidation therapy with durvalumab as standard of care (SoC) for patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC) and no progression after platinum-based cCRT. To improve outcomes further in this population, novel immunotherapy combinations that build on the backbone of PD-L1 inhibition with durvalumab are being explored. Domvanalimab (AB154) is an Fc-silent humanised IgG1 MoAb that blocks interaction of the T cell immunoreceptor with Ig and ITIM domains (TIGIT; upregulated by immune cells) with CD112 and CD155 (expressed by tumour and antigen-presenting cells), reducing inhibition of T cells and natural killer cells and, thereby, promoting antitumour activity. The combination of TIGIT inhibition with PD-(L)1 inhibition has shown encouraging activity in phase 1 and 2 trials in metastatic NSCLC, with enriched benefit observed among pts with PD-L1 positive tumours (Rodriguez-Abreu, et al. 2020; Niu, et al. 2020). PACIFIC-8 (NCT05211895) is assessing the efficacy and safety of durvalumab combined with domvanalimab as consolidation therapy in pts with unresectable Stage III NSCLC and PD-L1 tumour cell (TC) expression.

Trial design

PACIFIC-8 is a phase 3, double-blind, placebo (pbo)-controlled randomised global trial. Eligible pts (≥18 years) must have PD-L1 positive, unresectable Stage III NSCLC (TC expression ≥1% by central lab; VENTANA SP263 IHC assay), WHO performance status 0/1, documented EGFR/ALK wild-type tumour status and not have progressed following definitive platinum-based cCRT (≥2 cycles). Pts (N∼860) will be randomised (1:1) to receive SoC durvalumab (1500 mg IV) combined with either domvanalimab (20 mg/kg IV) or pbo, every 4 weeks for up to 12 months. The primary endpoint is progression-free survival (PFS; RECIST v1.1; BICR) in pts with PD-L1 TC ≥50%. Secondary endpoints include PFS (RECIST v1.1; BICR) in pts with PD-L1 TC ≥1%, overall survival, objective response rate and duration of response (RECIST v1.1; BICR), safety/tolerability, and pt-reported outcomes. Enrolment is ongoing.

Clinical trial identification

NCT05211895, release date: January 27, 2022.

Editorial acknowledgement

Medical writing support for the development of this abstract, under the direction of the authors, was provided by Aaron Korpal, PhD, and Andrew Gannon, MS, MA, of Ashfield MedComms (Manchester, UK), an Ashfield Health company.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

M. Ozguroglu: Non-Financial Interests, Personal and Institutional, Invited Speaker, ESMO IO Geneva: AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Regeneron, Bayer; Other, Personal and Institutional, Principal Investigator, Financial and non-financial interest: AstraZeneca, MSD, Roche, Bayer, Gilead, Novartis, Sanofi, Janssen, Regeneron; Other, Personal, Member, Steering committee membership; Financial and non-financial interest: AstraZeneca, Bayer, Regeneron. B. Levy: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Jannsen, Daiichi Sankyo, Takeda, Genentech, Eli Lilly, Novartis, Amgen, Mirati. H. Horinouchi: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Eli Lilly, Ono, BMS, Chugai, Roche, Kyowa-Kirin, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca, Eli Lilly, Chugai, Roche, Ono, BMS, MSD; Financial Interests, Institutional, Research Grant: MSD, AbbVie, AstraZeneca, BMS, Ono, Merck Biopharma, Daiichi-Sankyo, Janssen, Genomic Health, Chugai, Roche, Novartis. E. Grainger: Financial Interests, Personal and Institutional, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Ownership Interest: AstraZeneca. P. Phuong: Financial Interests, Institutional, Full or part-time Employment: Arcus; Financial Interests, Institutional, Stocks/Shares: Arcus. D.A. Peterson: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. M. Newton: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Spira: Financial Interests, Personal, Stocks/Shares: Eli Lilly; Financial Interests, Institutional, Funding: LAM Therapeutics, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, AbbVie, Ignyta, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, Rubius, Synthekine, Mersana, Blueprint Medicines; Financial Interests, Personal, Advisory Role: Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Mersana, Gritstone Bio, Daiichi-Sankyo/AstraZeneca, Array BioPharma, AstraZeneca/MedImmune, Merck, Bristol-Myers Squibb, Blueprint Medicines; Financial Interests, Personal, Other, Honoraria: CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol-Myers Squibb, Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.